Howard Capital Management Inc. Buys 67 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Howard Capital Management Inc. boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 3.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,304 shares of the company’s stock after purchasing an additional 67 shares during the quarter. Howard Capital Management Inc.’s holdings in IDEXX Laboratories were worth $953,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the company. Outlook Wealth Advisors LLC boosted its stake in IDEXX Laboratories by 10.0% in the third quarter. Outlook Wealth Advisors LLC now owns 707 shares of the company’s stock valued at $357,000 after acquiring an additional 64 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of IDEXX Laboratories by 17.1% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 27,321 shares of the company’s stock valued at $13,982,000 after purchasing an additional 3,984 shares during the last quarter. Forsta AP Fonden boosted its position in shares of IDEXX Laboratories by 6.2% in the 3rd quarter. Forsta AP Fonden now owns 32,600 shares of the company’s stock worth $16,470,000 after purchasing an additional 1,900 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its stake in IDEXX Laboratories by 197.1% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 29,634 shares of the company’s stock worth $14,972,000 after buying an additional 19,659 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale increased its position in IDEXX Laboratories by 1.1% during the 3rd quarter. DekaBank Deutsche Girozentrale now owns 54,792 shares of the company’s stock valued at $27,892,000 after buying an additional 572 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 13,330 shares of company stock valued at $6,161,276. Company insiders own 2.11% of the company’s stock.

Analyst Ratings Changes

Several brokerages have weighed in on IDXX. Leerink Partners assumed coverage on IDEXX Laboratories in a report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 price target for the company. Barclays lifted their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the company a “neutral” rating in a research note on Tuesday, February 4th. StockNews.com downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, February 5th. Finally, Morgan Stanley cut their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Trading Down 0.0 %

Shares of IDEXX Laboratories stock opened at $452.77 on Monday. The stock has a market cap of $37.08 billion, a PE ratio of 42.43, a price-to-earnings-growth ratio of 3.41 and a beta of 1.37. The firm has a fifty day moving average price of $431.92 and a 200 day moving average price of $452.18. IDEXX Laboratories, Inc. has a 1 year low of $398.50 and a 1 year high of $583.39. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.